Amgen’s Cannibalistic Ways
If you don’t think that Amgen is excited about its future, check out what the company is piling on its plate. The biotech giant will be earmarking half of next year’s revenue to launch a $5 billion share buyback.
FDA Chief Eyes Path for Copycat Biotech Drugs
Food and Drug Administration Commissioner Mark McClellan said on Friday it may be justifiable for regulators to approve generic forms of biotech drugs even if they have not been through the same lengthy clinical trials required of the original drugs.
Boston’s Biotech Moment
The future is moving out of dusty library stacks and into pristine laboratories on both sides of the Charles River, making this area the national leader in biotechnology. The boom is driven by a new breed of intellectual wearing a white lab coat and using science to breach the barrier between academia and commerce.
Professor, Biotech Butt Heads
Ignacio Chapela, an ecologist known for his controversial research on genetically modified corn, is turning a career setback into a call for action among scientists opposed to the influence of corporate interests on academic research.
Chapela, who was denied tenure last month at the University of California at Berkeley, is now accusing the institution of trying to please the biotech industry by shutting him out.
Tech Transfer: The Ties That Bind
Did you know that the lack of an IPO window, depressed market conditions and a downturn in venture financing affect not only companies but also universities? That’s because so many academic institutions are tied to the fortunes of companies, both small and large, through their technology transfer agreements.